Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025)

Candel Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $4.4 million for Q4 2023.

  • On a quarterly basis, Accumulated Expenses fell 7.77% to $4.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.4 million, a 7.77% decrease, with the full-year FY2023 number at $4.4 million, down 7.77% from a year prior.
  • Accumulated Expenses hit $4.4 million in Q4 2023 for Candel Therapeutics, up from $3.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CADL hit a ceiling of $4.7 million in Q4 2022 and a floor of $1.1 million in Q2 2021.
  • Historically, Accumulated Expenses has averaged $3.1 million across 4 years, with a median of $3.3 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 243.08% in 2022 and later plummeted 60.34% in 2023.
  • Tracing CADL's Accumulated Expenses over 4 years: stood at $3.1 million in 2020, then crashed by 33.29% to $2.1 million in 2021, then soared by 125.33% to $4.7 million in 2022, then fell by 7.77% to $4.4 million in 2023.
  • Business Quant data shows Accumulated Expenses for CADL at $4.4 million in Q4 2023, $3.4 million in Q3 2023, and $3.5 million in Q2 2023.